The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 347:1287-1288 October 17, 2002 Number 16
NextNext

Weight Loss in HIV-Infected Patients

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Recent reports have highlighted the risk of hyperlactatemia and multiorgan failure in human immunodeficiency virus (HIV)–infected patients receiving interferon plus ribavirin for chronic hepatitis C.1,2 The mitochondrial toxicity of nucleoside analogues seems to be associated with these effects. Hyperlactatemia and pancreatitis have also recently been reported in patients taking didanosine and ribavirin.2,3 Since in vitro studies have shown that the presence of ribavirin reduces the amount of didanosine needed to suppress HIV,3 it is not surprising that potentiation of didanosine by ribavirin may increase its toxicity. Available data seem to confirm that there is a greater risk . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.